Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,731.75 -311.95 (-0.49%) CMC Crypto 200
1,323.32 -73.22 (-5.24%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 25.04 |
| Open | 26.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 26.06 - 26.06 |
| 52-week range | 25.04 - 34.47 |
| Volume | |
| Avg. volume | 10,024 |
| Market cap | 43B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 35.69 |
| EPS (TTM) | 0.73 |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (4.96%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
ZacksDown -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
Business WireTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
OSAKA, Japan & CAMBRIDGE, Mass., April 26, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when de
